Dynamic Financial Group Has $1.51 Million Holdings in Pfizer Inc. $PFE

Dynamic Financial Group increased its position in Pfizer Inc. (NYSE:PFE) by 3.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 62,439 shares of the biopharmaceutical company’s stock after acquiring an additional 1,874 shares during the quarter. Pfizer comprises about 1.5% of Dynamic Financial Group’s holdings, making the stock its 9th biggest holding. Dynamic Financial Group’s holdings in Pfizer were worth $1,514,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer in the first quarter valued at approximately $28,000. Horizon Financial Services LLC purchased a new stake in Pfizer in the first quarter valued at approximately $35,000. Finally, WPG Advisers LLC purchased a new stake in Pfizer in the first quarter valued at approximately $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 1.7%

Shares of NYSE PFE opened at $24.81 on Monday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.82. The firm’s fifty day moving average is $24.86 and its 200 day moving average is $24.12. The company has a market cap of $141.03 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm earned $0.60 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Morgan Stanley lowered their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.